MyChart access returning to Kettering Health patients: Update
According to Kettering Health officials, MyChart is once again available to patients with nearly all of its functionality.
Kettering Health patients speak out on aftermath of cyberattack
Patients can use MyChart to schedule and view upcoming appointments, view prescription lists, message providers and view test results.
Kettering Health says patients may receive extra notifications from MyChart as they continue to restore patient data to EPIC, their electronic medical record system.
'This process— called 'backfill'— updates patient records in real time. When that happens, MyChart automatically sends text and email notifications to let you know,' said Kettering Health.
Officials remind patients to remain vigilant when reviewing any digital communications, as there are still reports of several scams surfacing after the cyberattack.
For more information and frequently asked questions, visit Kettering Health's website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Will the west Dayton hospital proposal make it onto the November ballot?
DAYTON, Ohio (WDTN) — The decision to build a new hospital in west Dayton could be in the hands of voters this November. The Clergy Community Coalition held a press conference on Tuesday to announce progress toward reaching their goal. 'We are very pleased to announce that we're turning in 2,800 signatures into the clerk of the commission,' said Bishop Richard Cox, CCC president. It was back to the drawing board after Dayton City Commissioners were split with a 2-2 vote and one abstention just three weeks ago over the imitative to add the hospital petition to the ballot. In just 20 days, the coalition gathered even more signatures from the community, in order to put it on the ballot regardless of the commission's vote. The CCC says it's a step in the right direction, and couldn't have been done without the community's support. 'I think it's a win-win for the city. It would provide adequate health care and alleviate the health care desert that we're now living in,' said Cox. 'It's also a win-win for the city commission because then the politicians that we elected to serve us can still work with us as we pursue this effort.' If the petition goes through the Montgomery County Board of Elections once all the signatures are verified, it will be up to the people of Dayton to make the choice in November. However, the coalition says they still want to work with the commissioners regardless of how they initially voted. 'We're still interested in working with you. We elected you to serve us, and we want to work with you to make sure that the citizens of Dayton in this upcoming election, get the services they need from the people that they have elected,' said Cox. However, if the initiative does pass, there will not be adequate money to immediately build a hospital. The coalition says they plan to go to the state and some potential partners for investment money, although they have not revealed who those partners would be. They also say they are not naive to think the project will happen overnight. But they do have some target goals in mind. 'It's all incremental and it will take time. But our hope would be that we have something standing by 2032,' said Nancy Kiehl, CCC secretary. 2 NEWS reached out to Dayton City Commissioners for comment, with one commissioner replying that he would share a statement once the signatures were verified and in the hands of the board of elections. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
13 hours ago
- Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablation Submitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months. Treated 40 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study in Europe. Endocardial Catheter AF Ablation Submitted FDA IDE application, including the pivotal study protocol, and remain on track to commence the IDE pivotal study in the next few months. Observed improved procedure times since last presented at the Heart Rhythm Society 2025 Meeting in April. Treated over 140 total patients with the nsPFA 360° catheter to date as part of the multi-center, first-in-human AF study in Europe. 'We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs,' said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. 'I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360° catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe. These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease, AF and additional diseases in the future.' Second Quarter 2025 Financial Results Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended June 30, 2025, were $20.3 million, an increase of $8.5 million compared to $11.7 million in the prior year period. The increase was primarily driven by administrative expenses related to the expanding organization to support advancement of the nsPFA device clinical trials and commercialization, and non-cash stock-based compensation and other compensation. Non-GAAP costs and expenses for the three months ended June 30, 2025, were $14.8 million, an increase of $5.4 million compared to $9.4 million in the prior year period. GAAP net loss for the three months ended June 30, 2025 was ($19.2) million compared to ($11.4) million for the three months ended June 30, 2024. Non-GAAP net loss for the three months ended June 30, 2025 was ($13.7) million compared to ($9.0) million for the three months ended June 30, 2024. Cash and cash equivalents totaled $106.3 million as of June 30, 2025, compared to $26.2 million as of June 30, 2024 and $119.3 million as of March 31, 2025. Cash used in operating activities in the second quarter of 2025 totaled $12.8 million, compared to $8.4 million used in the same period in the prior year, and $13.5 million used in the first quarter of 2025. Reconciliations of GAAP to Non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading 'Non-GAAP Financial Measures.' Webcast and Conference Call Information Pulse Biosciences' management will host a conference call today, August 12, 2025, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available at About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Non-GAAP Financial Measures In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, restructuring, severance, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization, restructuring costs, severance expense and legal settlement expenses. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's future commercialization and product development efforts and whether those efforts will be successful, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nsPFA 360° Cardiac Catheter System, the nsPFA Cardiac Surgical System, and the nsPFA Percutaneous Electrode System, and statements concerning the Company's future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as 'may,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Product revenues $ — $ — $ — $ — Total revenues — — — — Cost and expenses: Research and development 12,088 7,230 22,401 13,971 General and administrative 8,187 4,496 15,918 8,370 Total cost and expenses 20,275 11,726 38,319 22,341 Loss from operations (20,275 ) (11,726 ) (38,319 ) (22,341 ) Other income: Interest income, net 1,107 343 2,356 821 Total other income 1,107 343 2,356 821 Net loss (19,168 ) (11,383 ) (35,963 ) (21,520 ) Comprehensive loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Net loss per share: Basic and diluted net loss per share $ (0.28 ) $ (0.20 ) $ (0.54 ) $ (0.38 ) Weighted average shares used to compute net loss per common share — basic and diluted 67,276 57,180 67,201 57,152 Expand Reconciliation of GAAP to Non-GAAP Financial Measures The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: (In thousands) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Reconciliation of GAAP to non-GAAP Research and development: GAAP Research and development $ 12,088 $ 7,230 $ 22,401 $ 13,971 Less: Stock-based compensation expense (2,335 ) (1,001 ) (5,097 ) (1,950 ) Less: Depreciation and amortization (44 ) (52 ) (90 ) (105 ) Non-GAAP Research and development $ 9,709 $ 6,177 $ 17,214 $ 11,916 Reconciliation of GAAP to non-GAAP General and administrative: GAAP General and administrative $ 8,187 $ 4,496 $ 15,918 $ 8,370 Less: Stock-based compensation expense (2,854 ) (1,051 ) (5,773 ) (1,861 ) Less: Depreciation and amortization (229 ) (246 ) (466 ) (492 ) Add: Legal settlement — — 590 — Non-GAAP General and administrative $ 5,104 $ 3,199 $ 10,269 $ 6,017 Reconciliation of GAAP to non-GAAP Cost and expenses: GAAP Cost and expenses $ 20,275 $ 11,726 $ 38,319 $ 22,341 Less: Stock-based compensation expense (5,189 ) (2,052 ) (10,870 ) (3,811 ) Less: Depreciation and amortization (273 ) (298 ) (556 ) (597 ) Add: Legal settlement — — 590 — Non-GAAP Cost and expenses $ 14,813 $ 9,376 $ 27,483 $ 17,933 Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Add: Stock-based compensation expense 5,189 2,052 10,870 3,811 Add: Depreciation and amortization 273 298 556 597 Less: Legal settlement — — (590 ) — Non-GAAP Net loss $ (13,706 ) $ (9,033 ) $ (25,127 ) $ (17,112 ) Expand
Business Wire
14 hours ago
- Business Wire
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. 'Following the recent positive 36-month clinical data update with the OpRegen RPE cell therapy program, which is licensed by Genentech and Roche, we continue to remain confident in its potential to address a significant medical need, especially because long term clinical outcomes following a single administration of OpRegen cell therapy are challenging the long-held view that GA is an irreversible condition,' stated Brian M. Culley, Lineage CEO. 'It is notable that among patients who received extensive one-time coverage of OpRegen RPE cells across the area of atrophy, anatomical and functional benefits have lasted for at least three years, outcomes consistent with meaningful disease stabilization and even improvement.' 'In addition to supporting our partners in advancing the OpRegen program, we are equally excited to have reached a milestone with our OPC1 program for the treatment of spinal cord injury, treating our first-ever chronic patient with a new parenchymal spinal delivery system. We also solidified our position as a leader in allogeneic cell process development and manufacturing by reporting in-house GMP production for each of two separate cell-based product candidates from a master and working cell bank system which, in its current form, can support a production capability of several million doses for a single-administration product. This is in addition to continuing to advance our ReSonance TM program for the treatment of sensorineural hearing loss and evaluating other strategically selected early-stage initiatives. As our cell therapy platforms gain further validation, we believe our pipeline and cell manufacturing and related expertise continue to position us as a compelling partner and investment opportunity,' added Mr. Culley. Select Business Highlights RG6501 (OpRegen Cell Therapy) Positive RG6501 (OpRegen) Phase 1/2a Clinical Study 36 Month Results featured at Clinical Trials at the Summit (CTS) 2025. 2025 CTS highlights: Gains in Best Corrected Visual Acuity (BCVA) in patients in Cohort 4 (less advanced GA) measured at month 12 remain evident through month 36 following subretinal administration of OpRegen cell therapy; Mean change in BCVA among treated eyes for patients (n=10) completing 3-year follow up was +6.2 letters (compared to +5.5 letters at 24 months) (Early Treatment Diabetic Retinopathy Study (ETDRS) assessment); Improvement in BCVA and outer retinal structure in patients with extensive OpRegen bleb coverage of their GA area was greater than in patients with limited coverage and persisted through month 36 Effects were greater on average in the five (5) patients with extensive OpRegen cell therapy coverage of atrophic areas at the time of surgical delivery In these patients' treated eyes, the mean change in BCVA was +9.0 ETDRS letters for those completing 3-year follow-up (compared to +7.4 ETDRS letters at 24 months) (n=5) These data suggest that OpRegen cell therapy may counteract RPE cell dysfunction and loss in GA by providing support to the remaining retinal cells within atrophic areas, and these effects appear durable through at least 36 months after a single administration Ongoing execution of Lineage's contributions to its collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing Phase 2a clinical study (the 'GAlette Study') in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at sites in the U.S. and Israel. In addition to testing of other surgical parameters, Genentech currently plans to evaluate two proprietary surgical delivery devices that have potential advantages over available off-the-shelf devices in the GAlette Study. Ongoing efforts to further support development of OpRegen RPE cell therapy under a separate services agreement with Genentech, signed May 2024, including: (i) activities to support the ongoing Phase 1/2a study long term follow-up and the currently enrolling Phase 2a GAlette Study; and (ii) additional technical training and materials related to our cell therapy technology platform to support commercial manufacturing strategies. Manufacturing Capability Successfully completed a production run for two different product candidates, each produced from a customized, two-tiered current Good Manufacturing Practice ('cGMP') cell banking system, highlighting the application of the Lineage platform across multiple programs. This production process utilizes a genetically-stable master cell bank created from a single, well-characterized pluripotent cell line, to generate a working cell bank, which then provides the source material for a final cell-based product candidate. This demonstrated cGMP production process should enable the ability to produce millions of doses of a cost-effective, scalable and consistent supply of an allogeneic, cell-based product derived from a single initial cell line, that can be applied across multiple programs. OPC1 First chronic spinal cord injury patient treated in the DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. First chronic SCI patient treated in DOSED was a neurologically complete SCI injury (American Spinal Injury Association Impairment Scale [AIS] grade A), with a single neurological level of injury (NLI) from levels T1 to T10, and the novel delivery system successfully administered a one-time injection of OPC1. Hosted the 3 rd Annual Spinal Cord Injury Investor Symposium (3 rd SCIIS) in partnership with the Christopher & Dana Reeve Foundation. Balance Sheet Highlights Cash, cash equivalents, and marketable securities of $42.3 million as of June 30, 2025, is expected to support planned operations into Q1 2027. Second Quarter Operating Results Revenues: Revenue is generated primarily from collaboration revenues, royalties, and other revenues. Total revenues for the three months ended June 30, 2025 were $2.8 million, a net increase of $1.4 million as compared to $1.4 million for the same period in 2024. The increase was primarily driven by more collaboration revenue recognized from deferred revenues under the Roche Agreement, as well as deferred revenues recognized upon termination of the VAC platform-related collaboration agreement. Operating Expenses: Operating expenses are comprised of research and development ('R&D') expenses and general and administrative ('G&A') expenses. Total operating expenses for the three months ended June 30, 2025 were $22.5 million, an increase of $15.2 million as compared to $7.3 million for the same period in 2024. The overall increase was driven by the $14.8 million expense recognized for the loss on impairment for the intangible asset related to the VAC platform. R&D Expenses: R&D expenses for the three months ended June 30, 2025 were $3.1 million, an increase of $0.2 million as compared to $2.9 million for the same period in 2024. The net increase was primarily driven by ongoing activities within our preclinical programs. G&A Expenses: G&A expenses for the three months ended June 30, 2025 were $4.6 million, an increase of $0.2 million as compared to $4.4 million for the same period in 2024. The net increase was primarily driven by more costs incurred for services provided by third parties. Loss from Operations: Loss from operations for the three months ended June 30, 2025 were $19.8 million, an increase of $13.9 million as compared to $5.9 million for the same period in 2024. This increase in loss was primarily driven by the impairment expense related to the VAC platform of $14.8 million, which is a non-recurring transaction. Other Income/(Expenses): Other income/(expenses) for the three months ended June 30, 2025 reflected other expense of $10.6 million, compared to other income of $0.1 million for the same period in 2024. The net change was primarily attributable to the quarterly fair value remeasurement of the warrant liabilities of $12.7 million primarily due to an increase in our share price as compared to the prior quarter, partially offset by $1.7 million for exchange rate fluctuations related to Lineage's international subsidiaries. Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended June 30, 2025 was $30.5 million, or $0.13 per share (basic and diluted), compared to a net loss of $5.8 million, or $0.03 per share (basic and diluted), for the same period in 2024. The change was primarily driven by the loss on impairment expense related to a 2019 acquisition and the quarterly fair value remeasurement of the warrant liabilities. Conference Call and Webcast Interested parties may access the conference call on August 12, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the 'Lineage Cell Therapeutics Call'. A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through August 19 th, 2025, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 7788342. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen cell therapy, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit or follow the company on X/Twitter @LineageCell. Forward-Looking Statements Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. In some cases, forward-looking statements, can be identified by terms such as 'believe,' 'aim,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'design,' 'intend,' 'expect,' 'could,' 'can,' 'plan,' 'potential,' 'predict,' 'seek,' 'should,' 'would,' 'contemplate,' 'project,' 'target,' 'suggest,' or the negative version of these words and similar expressions. Such forward-looking statements include, but are not limited to, statements relating to: the potential therapeutic benefits of OpRegen cell therapy in patients with GA secondary to AMD and the significance of the Phase 1/2a clinical study data reported to date; the benefits of our services agreement with Genentech and its impact on advancing the OpRegen cell therapy program; Lineage's ability to produce millions of doses of a cost-effective, and consistent supply of an allogeneic cell, cell-based product derived from a single initial cell line across one or more programs; the plans and expectations with respect to OPC1; the potential continued development of ReSonance (ANP1); Lineage's belief that its pipeline and expertise will position it as a compelling partner and investment opportunity; and that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the first quarter of 2027. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to expend our cash, cash equivalents and marketable securities more quickly than expected; that development activities, preclinical activities, and clinical trials of our product candidates may not commence, progress or be completed as expected due to many factors within and outside of our control; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that Roche and Genentech may not successfully advance OpRegen cell therapy or be successful in completing further clinical trials for OpRegen cell therapy and/or obtaining regulatory approval for OpRegen cell therapy in any particular jurisdiction; that competing alternative therapies may adversely impact the commercial potential of OpRegen cell therapy; that OPC1 clinical trials may not be successful; that the ongoing Israeli regional conflict may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. Further information regarding these and other risks is included under the heading 'Risk Factors' in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available on the SEC's website at You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Lineage undertakes no obligation to update any forward-looking statement to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. December 31, 2024 ASSETS CURRENT ASSETS Cash and cash equivalents $ 42,271 $ 45,789 Marketable securities 17 2,016 Accounts receivable 256 638 Prepaid expenses and other current assets 1,300 2,554 Total current assets 43,844 50,997 NONCURRENT ASSETS Property and equipment, net 2,255 2,251 Operating lease right-of-use assets 1,817 2,144 Deposits and other long-term assets 511 614 Goodwill 10,672 10,672 Intangible assets, net 31,700 46,540 TOTAL ASSETS $ 90,799 $ 113,218 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 4,451 $ 5,437 Operating lease liabilities, current portion 998 1,097 Finance lease liabilities, current portion 50 55 Deferred revenues, current portion 5,257 7,388 Total current liabilities 10,756 13,977 LONG-TERM LIABILITIES Deferred tax liability 273 273 Deferred revenues, net of current portion 12,751 14,433 Operating lease liabilities, net of current portion 1,058 1,295 Finance lease liabilities, net of current portion 48 67 Warrant liabilities 18,801 6,161 TOTAL LIABILITIES 43,687 36,206 Commitments and contingencies (Note 13) SHAREHOLDERS' EQUITY Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common shares, no par value, 450,000 shares authorized as of June 30, 2025 and December 31, 2024; 228,356 and 220,416 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 490,551 484,722 Accumulated other comprehensive loss (4,098 ) (2,876 ) Accumulated deficit (438,068 ) (403,465 ) Lineage's shareholders' equity 48,385 78,381 Noncontrolling deficit (1,273 ) (1,369 ) Total shareholders' equity 47,112 77,012 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 90,799 $ 113,218 Expand LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES: Collaboration revenues $ 2,532 $ 1,098 $ 3,802 $ 2,285 Royalties, license and other revenues 233 310 465 567 Total revenues 2,765 1,408 4,267 2,852 OPERATING EXPENSES: Cost of royalties 39 44 75 142 Research and development 3,106 2,868 6,220 5,878 General and administrative 4,560 4,363 9,417 9,360 Loss on impairment of intangible asset (Note 6 and Note 13) 14,840 — 14,840 — Total operating expenses 22,545 7,275 30,552 15,380 Loss from operations (19,780 ) (5,867 ) (26,285 ) (12,528 ) OTHER INCOME (EXPENSES): Interest income, net 454 463 932 925 Loss on marketable equity securities, net (2 ) (10 ) (7 ) (15 ) Change in fair value of warrant liability (12,740 ) — (10,435 ) — Foreign currency transaction gain (loss), net 1,678 (378 ) 1,447 (732 ) Other income (expense), net 26 19 (159 ) 19 Total other income (expenses) (10,584 ) 94 (8,222 ) 197 Net (income) loss attributable to noncontrolling interest (100 ) 13 (96 ) 29 Net loss per common share attributable to Lineage basic and diluted $ (0.13 ) $ (0.03 ) $ (0.15 ) $ (0.07 ) Weighted-average common shares used to compute basic and diluted net loss per common share 228,356 188,813 227,212 185,861 Expand LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) (UNAUDITED) Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss attributable to Lineage $ (34,603 ) $ (12,302 ) Net income (loss) attributable to noncontrolling interest 96 (29 ) Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities: Issuance costs for common stock warrant liabilities 183 — Loss on impairment of intangible asset 14,840 — Loss on marketable equity securities, net 7 15 Accretion of income on marketable debt securities (10 ) (102 ) Depreciation and amortization expense 335 295 Change in right-of-use assets and liabilities (88 ) (20 ) Amortization of intangible assets — 22 Stock-based compensation 2,455 2,432 Change in fair value of warrant liability 10,435 — Foreign currency remeasurement and other loss (1,455 ) 767 Changes in operating assets and liabilities: Accounts receivable 381 508 Prepaid expenses and other current assets 1,271 516 Accounts payable and accrued liabilities (459 ) (1,245 ) Deferred revenue (3,813 ) (1,816 ) Net cash used in operating activities (10,425 ) (10,959 ) CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from the sale of marketable equity securities — 18 Purchases of marketable debt securities — (8,761 ) Maturities of marketable debt securities 2,000 — Purchase of equipment (111 ) (88 ) Net cash (used in) provided by investing activities 1,889 (8,831 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from employee options exercised — 219 Common shares received and retired for employee taxes paid (15 ) (23 ) Proceeds from sale of common shares under ATM, net of offering costs — 68 Proceeds from sale of common shares under registered direct financing, net of offering costs — 13,889 Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs 5,232 — Payment of financed insurance premium (452 ) — Payment of finance lease liabilities (28 ) (27 ) Net cash provided by financing activities 4,737 14,126 Effect of exchange rate changes on cash, cash equivalents and restricted cash 220 (158 ) (3,579 ) (5,822 ) CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At beginning of the period 46,354 35,992 At end of the period $ 42,775 $ 30,170 Expand
